First report of the safety, tolerability, and pharmacokinetics of saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Onozawa Y, et al. Eur J Cancer 2011;47(Suppl 1):S160 (poster)

Pharmacological cardioversion of atrial fibrillation – a double-blind, randomized, placebo-controlled, multicentre,
dose-escalation study of AZD1305 given intravenously. Rσnaszιki A, et al. Europace 2011;13:1148–56

QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation:
a double-blind, randomized, placebo-controlled trial. Egstrup K, et al. Am J Cardiovasc Drugs 2011;11:199–208

A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter. Toivonen L, et al. J Cardiovasc Pharmacol 2010;56:300–8

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. Hannon RA, et al. J Bone Miner Res 2010;25:463–71

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Baselga J, et al. Clin Cancer Res 2010;16:4876–83

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Boss DS, et al. Ann Oncol 2010;21:884–94

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer. James ND, et al. Eur Urol 2009;55:1112–1123

Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Geller JC, et al. J Clin Pharmacol 2009;49:312–22

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Green TP, et al. Mol Oncol 2009;3:248–61

Zibotentan. James ND and Growcott JW. Drugs Fut 2009;34:624–34